eBOOK: mRNA-LNPs for vaccine and gene therapy indications

Messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNPs) has emerged as a transformative modality in both vaccine development and gene therapy. This innovative technology combines the programmability of nucleic acids with the protective and targeting capabilities of nanoparticles, offering a powerful, non-viral strategy for introducing nucleic acids into cells. The regulatory acceptance and success of mRNA-LNP-based COVID-19 vaccines has opened the potential of this technology beyond infectious diseases and into the realms of oncology, rare genetic disorders and personalized medicine.